Q2054 Lisocabtagene maraleucel - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Lisocabtagene maraleucel

Brand Name:

Breyanzi

Strength:

HCPCS:

Q2054

SEER*Rx Category:

Immunotherapy

Major Drug Class:

CAR-T

Minor Drug Class:

CD19

Oral (Y/N):

No

FDA Approval Year:

2021

FDA Discontinuation Year:

CMS Effective Date:

Sept. 27, 2021

CMS Discontinuation Date:

Status:

In Use